Skip to content

H.R. 5547 · 118th Congress (2023–2025)

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Show official title

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 5547’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Wiley Nickel (D-NC-13)
Cosponsors
28 cosponsors

2 original · 26 later

23 R · 5 D

  1. Rep. Donald G. Davis (D-NC-1)· Original · Sep 18, 2023
  2. Rep. John Joyce (R-PA-13)· Original · Sep 18, 2023
  3. Rep. Scott H. Peters (D-CA-50)· Later · Nov 1, 2023
  4. Rep. Dan Crenshaw (R-TX-2)· Later · Nov 14, 2023
  5. Rep. Larry Bucshon (R-IN-8)· Later · Nov 30, 2023
  6. Rep. Richard Hudson (R-NC-9)· Later · Dec 6, 2023
  7. Rep. A. Drew Ferguson IV (R-GA-3)· Later · Dec 11, 2023
  8. Rep. Rick W. Allen (R-GA-12)· Later · Feb 23, 2024
  9. Rep. Diana Harshbarger (R-TN-1)· Later · Mar 1, 2024
  10. Rep. Daniel Meuser (R-PA-9)· Later · Mar 19, 2024
  11. Rep. Blake D. Moore (R-UT-1)· Later · Mar 19, 2024
  12. Rep. Adrian Smith (R-NE-3)· Later · Mar 19, 2024
  13. Rep. Mariannette Miller-Meeks (R-IA-1)· Later · Mar 21, 2024
  14. Rep. Nicole Malliotakis (R-NY-11)· Later · Apr 10, 2024
  15. Rep. Vern Buchanan (R-FL-16)· Later · May 1, 2024
  16. Rep. Mike Carey (R-OH-15)· Later · May 15, 2024
  17. Rep. Beth Van Duyne (R-TX-24)· Later · May 15, 2024
  18. Rep. Sheila Cherfilus-McCormick (D-FL-20)· Later · May 23, 2024
  19. Rep. Mike Kelly (R-PA-16)· Later · May 23, 2024
  20. Rep. Lloyd Smucker (R-PA-11)· Later · Jun 14, 2024
  21. Rep. Michael C. Burgess (R-TX-26)· Later · Aug 27, 2024
  22. Rep. Neal P. Dunn (R-FL-2)· Later · Sep 10, 2024
  23. Rep. Josh Gottheimer (D-NJ-5)· Later · Sep 10, 2024
  24. Rep. Claudia Tenney (R-NY-24)· Later · Sep 10, 2024
  25. Rep. Kevin Hern (R-OK-1)· Later · Oct 29, 2024
  26. Rep. August Pfluger (R-TX-11)· Later · Oct 29, 2024
  27. Rep. Ken Calvert (R-CA-41)· Later · Dec 5, 2024
  28. Rep. Joseph D. Morelle (D-NY-25)· Later · Dec 5, 2024
Policy area
Health
Subjects
  • Genetics
  • Medicare
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 3 committee actions · Sep 18, 2023 – Dec 17, 2024
    1. Referred to committee

      Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
    3. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Sep 18, 2023
  2. HouseHealthReferred Sep 22, 2023
    1. Feb 29, 2024 · Hearing

  3. HouseWays and MeansReferred Sep 18, 2023
  4. HouseHealthReferred Dec 17, 2024

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Maintaining Investments in New Innovation Act

    Display title, Short title · Introduced in House

  2. To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

    Official title · Introduced in House